USD 2.17
(-0.46%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 109.97 Million USD | 13.39% |
2022 | 96.99 Million USD | 144.16% |
2021 | 39.72 Million USD | -10.81% |
2020 | 44.54 Million USD | 6.59% |
2019 | 41.78 Million USD | 33.43% |
2018 | 31.31 Million USD | 65.42% |
2017 | 18.93 Million USD | 100.08% |
2016 | 9.46 Million USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 2.28 Million USD | 0.0% |
2024 Q1 | 2.52 Million USD | -100.0% |
2023 Q4 | 109.97 Million USD | 5.32% |
2023 Q1 | 99.27 Million USD | 2.35% |
2023 Q2 | 101.82 Million USD | 2.57% |
2023 FY | 109.97 Million USD | 13.39% |
2023 Q3 | 104.42 Million USD | 2.56% |
2022 Q3 | 102.84 Million USD | 0.91% |
2022 Q1 | 96.49 Million USD | 142.89% |
2022 Q2 | 101.91 Million USD | 5.62% |
2022 Q4 | 96.99 Million USD | -5.68% |
2022 FY | 96.99 Million USD | 144.16% |
2021 Q3 | 41.43 Million USD | 0.04% |
2021 Q4 | 39.72 Million USD | -4.12% |
2021 Q2 | 41.41 Million USD | -4.58% |
2021 Q1 | 43.4 Million USD | -2.56% |
2021 FY | 39.72 Million USD | -10.81% |
2020 FY | 44.54 Million USD | 6.59% |
2020 Q1 | 41.85 Million USD | 0.17% |
2020 Q2 | 41.92 Million USD | 0.17% |
2020 Q4 | 44.54 Million USD | 6.05% |
2020 Q3 | 42 Million USD | 0.17% |
2019 Q2 | 41.64 Million USD | 0.17% |
2019 Q3 | 41.71 Million USD | 0.17% |
2019 Q4 | 41.78 Million USD | 0.17% |
2019 FY | 41.78 Million USD | 33.43% |
2019 Q1 | 41.57 Million USD | 32.75% |
2018 Q2 | 19.18 Million USD | 0.0% |
2018 FY | 31.31 Million USD | 65.42% |
2018 Q4 | 31.31 Million USD | 0.45% |
2018 Q3 | 31.17 Million USD | 62.52% |
2018 Q1 | - USD | -100.0% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | 18.93 Million USD | 0.0% |
2017 FY | 18.93 Million USD | 100.08% |
2016 FY | 9.46 Million USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Abbott Laboratories | 13.59 Billion USD | 99.191% |
Allurion Technologies Inc. | 2.3 Million USD | -4669.211% |
Artivion, Inc. | 305.53 Million USD | 64.004% |
Avanos Medical, Inc. | 159.4 Million USD | 31.005% |
Butterfly Network, Inc. | 22.83 Million USD | -381.62% |
Butterfly Network, Inc. | 22.83 Million USD | -381.62% |
Bio-Rad Laboratories, Inc. | 1.18 Billion USD | 90.754% |
Boston Scientific Corporation | 8.96 Billion USD | 98.773% |
CONMED Corporation | 971.48 Million USD | 88.679% |
Edwards Lifesciences Corporation | 670 Million USD | 83.585% |
Paragon 28, Inc. | 109.79 Million USD | -0.163% |
Glaukos Corporation | 383.73 Million USD | 71.34% |
Globus Medical, Inc. | 417.4 Million USD | 73.652% |
Inspire Medical Systems, Inc. | 24.84 Million USD | -342.639% |
Integer Holdings Corporation | 959.92 Million USD | 88.543% |
Medtronic plc | 23.87 Billion USD | 99.539% |
Myomo, Inc. | 115.16 Thousand USD | -95400.174% |
Nevro Corp. | 211.47 Million USD | 47.994% |
Owlet, Inc. | 22 Thousand USD | -499800.0% |
Penumbra, Inc. | 220.9 Million USD | 50.216% |
Vicarious Surgical Inc. | 13.78 Million USD | -697.809% |
Smith & Nephew plc | 2.17 Billion USD | 94.944% |
Sonendo, Inc. | 14.03 Million USD | -683.598% |
STERIS plc | 3.12 Billion USD | 96.475% |
Stryker Corporation | 10.9 Billion USD | 98.991% |
Zimmer Biomet Holdings, Inc. | 4.86 Billion USD | 97.741% |